| Year |
Citation |
Score |
| 2023 |
Olsen A, Locascio J, Tuncali I, Laroussi N, Abatzis E, Kamenskaya P, Kuras Y, Yi T, Videnovic A, Hayes M, Ho G, Paulson J, Khurana V, Herrington T, Hyman B, ... ... Schwarzschild M, et al. Health phenome of Parkinson's patients reveals prominent mood-sleep cluster. Research Square. PMID 38196602 DOI: 10.21203/rs.3.rs-3683455/v1 |
0.556 |
|
| 2023 |
Flores-Torres MH, Bjornevik K, Zhang X, Gao X, Hung AY, Schwarzschild MA, Chen X, Ascherio A. Hair color, family history of melanoma, and the risk of Parkinson's disease: An analysis update. Parkinsonism & Related Disorders. 119: 105965. PMID 38142631 DOI: 10.1016/j.parkreldis.2023.105965 |
0.364 |
|
| 2023 |
Srivastava P, Nishiyama S, Zhou F, Lin SH, Srivastava A, Su C, Xu Y, Peng W, Levy M, Schwarzschild M, Chen X. Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson's Disease. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. PMID 38110615 DOI: 10.1007/s11481-023-10094-7 |
0.346 |
|
| 2023 |
Xia N, Madore V, Albalakhi A, Lin S, Stimpson T, Xu Y, Schwarzschild MA, Bakshi R. Microglia-dependent neuroprotective effects of 4-octyl itaconate against rotenone-and MPP+-induced neurotoxicity in Parkinson's disease. Scientific Reports. 13: 15539. PMID 37730914 DOI: 10.1038/s41598-023-42813-8 |
0.323 |
|
| 2023 |
Palacios N, Wilkinson J, Bjornevik K, Schwarzschild MA, McIver L, Ascherio A, Huttenhower C. Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes. Annals of Neurology. PMID 37314861 DOI: 10.1002/ana.26719 |
0.375 |
|
| 2023 |
Di Luca DG, Macklin EA, Hodgeman K, Lopez G, Pothier L, Callahan KF, Lowell J, Chan J, Videnovic A, Lungu C, Lang AE, Litvan I, Schwarzschild MA, Simuni T. Enrollment of Participants From Marginalized Racial and Ethnic Groups: A Comparative Assessment of the STEADY-PD III and SURE-PD3 Trials. Neurology. Clinical Practice. 13: e200113. PMID 36865634 DOI: 10.1212/CPJ.0000000000200113 |
0.316 |
|
| 2022 |
Crotty GF, Keavney JL, Alcalay RN, Marek K, Marshall GA, Rosas HD, Schwarzschild MA. Planning for Prevention of Parkinson Disease: Now Is the Time. Neurology. 99: 1-9. PMID 36219787 DOI: 10.1212/WNL.0000000000200789 |
0.351 |
|
| 2022 |
Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, ... ... Schwarzschild MA, et al. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 23: 855. PMID 36203214 DOI: 10.1186/s13063-022-06703-0 |
0.64 |
|
| 2022 |
Zhang X, Molsberry SA, Schwarzschild MA, Ascherio A, Gao X. Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease. Jama Network Open. 5: e2227738. PMID 35984656 DOI: 10.1001/jamanetworkopen.2022.27738 |
0.339 |
|
| 2022 |
Crotty GF, Schwarzschild MA. What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs. Neurology. 99: 34-41. PMID 35970592 DOI: 10.1212/WNL.0000000000200238 |
0.349 |
|
| 2022 |
Molsberry SA, Hughes KC, Schwarzschild MA, Ascherio A. Who to Enroll in Parkinson Disease Prevention Trials? The Case for Composite Prodromal Cohorts. Neurology. 99: 26-33. PMID 35970591 DOI: 10.1212/WNL.0000000000200788 |
0.336 |
|
| 2022 |
Berg D, Crotty GF, Keavney JL, Schwarzschild MA, Simuni T, Tanner C. Path to Parkinson Disease Prevention: Conclusion and Outlook. Neurology. 99: 76-83. PMID 35970586 DOI: 10.1212/WNL.0000000000200793 |
0.34 |
|
| 2022 |
Page A, Yung N, Auinger P, Venuto C, Glidden A, Macklin E, Omberg L, Schwarzschild MA, Dorsey ER. A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson's Disease Clinical Trial: A Pilot Study. Digital Biomarkers. 6: 1-8. PMID 35224425 DOI: 10.1159/000521232 |
0.314 |
|
| 2022 |
Sanchez AV, Ison JM, Hemley H, Willis A, Siddiqi B, Macklin EA, Ulysse C, Reynolds M, Schwarzschild MA, Jackson JD. Designing the fostering inclusivity in research engagement for underrepresented populations in Parkinson's disease study. Contemporary Clinical Trials. 106713. PMID 35202842 DOI: 10.1016/j.cct.2022.106713 |
0.314 |
|
| 2022 |
Cai W, Srivastava P, Feng D, Lin Y, Vanderburg CR, Xu Y, Mclean P, Frosch MP, Fisher DE, Schwarzschild MA, Chen X. Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson's disease. Molecular Neurodegeneration. 17: 16. PMID 35197079 DOI: 10.1186/s13024-022-00520-4 |
0.666 |
|
| 2022 |
Zhang X, Molsberry SA, Yeh TS, Cassidy A, Schwarzschild MA, Ascherio A, Gao X. Intake of Flavonoids and Flavonoid-Rich Foods, and Mortality Risk Among Individuals With Parkinson Disease: A Prospective Cohort Study. Neurology. PMID 35082171 DOI: 10.1212/WNL.0000000000013275 |
0.337 |
|
| 2022 |
Macklin EA, Ascherio A, Schwarzschild MA. Effect of Urate-Elevating Inosine on Progression of Early Parkinson Disease-Reply. Jama. 327: 85-86. PMID 34982121 DOI: 10.1001/jama.2021.21011 |
0.307 |
|
| 2021 |
Lungu C, Cedarbaum JM, Dawson TM, Dorsey ER, Faraco C, Federoff HJ, Fiske B, Fox R, Goldfine AM, Kieburtz K, Macklin EA, Matthews H, Rafaloff G, Saunders-Pullman R, Schor NF, ... Schwarzschild MA, et al. Seeking progress in disease modification in Parkinson disease. Parkinsonism & Related Disorders. PMID 34561166 DOI: 10.1016/j.parkreldis.2021.09.006 |
0.359 |
|
| 2021 |
Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, Kamp C, Lungu C, Macklin EA, Marek K, Mozaffarian D, Oakes D, Rudolph A, Shoulson I, Videnovic A, et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. Jama. 326: 926-939. PMID 34519802 DOI: 10.1001/jama.2021.10207 |
0.377 |
|
| 2021 |
Liu G, Peng J, Liao Z, Locascio JJ, Corvol JC, Zhu F, Dong X, Maple-Grødem J, Campbell MC, Elbaz A, Lesage S, Brice A, Mangone G, Growdon JH, Hung AY, ... Schwarzschild MA, et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nature Genetics. PMID 33958783 DOI: 10.1038/s41588-021-00847-6 |
0.557 |
|
| 2021 |
Zhang X, Molsberry SA, Pavlova M, Schwarzschild MA, Ascherio A, Gao X. Association of Sleepwalking and REM Sleep Behavior Disorder With Parkinson Disease in Men. Jama Network Open. 4: e215713. PMID 33847749 DOI: 10.1001/jamanetworkopen.2021.5713 |
0.31 |
|
| 2021 |
Tanner CM, Cummings SR, Schwarzschild MA, Brown EG, Dorsey ER, Espay AJ, Galifianakis NB, Goldman SM, Litvan I, Luthra N, McFarland NR, Mitchell KT, Standaert DG, Bauer DC, Greenspan SL, et al. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. Npj Parkinson's Disease. 7: 16. PMID 33649343 DOI: 10.1038/s41531-021-00162-1 |
0.585 |
|
| 2020 |
Schneider RB, Omberg L, Macklin EA, Daeschler M, Bataille L, Anthwal S, Myers TL, Baloga E, Duquette S, Snyder P, Amodeo K, Tarolli CG, Adams JL, Callahan KF, Gottesman J, ... ... Schwarzschild MA, et al. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). Annals of Clinical and Translational Neurology. PMID 33350601 DOI: 10.1002/acn3.51236 |
0.32 |
|
| 2020 |
Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease? Parkinsonism & Related Disorders. 45-53. PMID 33349580 DOI: 10.1016/j.parkreldis.2020.10.024 |
0.392 |
|
| 2020 |
Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, et al. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. Jama Neurology. PMID 33315105 DOI: 10.1001/jamaneurol.2020.4725 |
0.345 |
|
| 2020 |
Hung AY, Schwarzschild MA. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 33205384 DOI: 10.1007/s13311-020-00964-w |
0.328 |
|
| 2020 |
Crotty GF, Maciuca R, Macklin EA, Wang J, Montalban M, Davis SS, Alkabsh JI, Bakshi R, Chen X, Ascherio A, Astarita G, Huntwork-Rodriguez S, Schwarzschild MA. Association of caffeine and related analytes with resistance to Parkinson's disease among mutation carriers: A metabolomic study. Neurology. PMID 32999056 DOI: 10.1212/WNL.0000000000010863 |
0.316 |
|
| 2020 |
Schootemeijer S, van der Kolk NM, Ellis T, Mirelman A, Nieuwboer A, Nieuwhof F, Schwarzschild MA, de Vries NM, Bloem BR. Barriers and Motivators to Engage in Exercise for Persons with Parkinson's Disease. Journal of Parkinson's Disease. PMID 32925106 DOI: 10.3233/Jpd-202247 |
0.373 |
|
| 2020 |
Molsberry S, Bjornevik K, Hughes KC, Healy B, Schwarzschild M, Ascherio A. Diet pattern and prodromal features of Parkinson's disease. Neurology. PMID 32817391 DOI: 10.1212/Wnl.0000000000010523 |
0.433 |
|
| 2020 |
Hasimoglu YG, Chen X, Bakshi R, Schwarzschild MA, Macklin EA. Does Serum Urate Change as Parkinson's Disease Progresses? Journal of Parkinson's Disease. 10: 1571-1576. PMID 32773396 DOI: 10.3233/Jpd-202064 |
0.446 |
|
| 2020 |
Ma C, Molsberry S, Li Y, Schwarzschild M, Ascherio A, Gao X. Dietary nicotine intake and risk of Parkinson disease: a prospective study. The American Journal of Clinical Nutrition. PMID 32725131 DOI: 10.1093/Ajcn/Nqaa186 |
0.438 |
|
| 2020 |
Crotty GF, Schwarzschild MA. Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression? Frontiers in Aging Neuroscience. 12: 186. PMID 32636740 DOI: 10.3389/Fnagi.2020.00186 |
0.452 |
|
| 2020 |
Huh YE, Ruby Chiang MS, Locascio JJ, Liao Z, Liu G, Choudhury K, Kuras YI, Tuncali I, Videnovic A, Hunt AL, Schwarzschild MA, Hung AY, Herrington TM, Hayes MT, Hyman BT, et al. β-Glucocerebrosidase Activity in -linked Parkinson's Disease: The Type of Mutation Matters. Neurology. PMID 32540937 DOI: 10.1212/Wnl.0000000000009989 |
0.62 |
|
| 2020 |
Palacios N, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Long-Term Use of Antibiotics and Risk of Parkinson's Disease in the Nurses' Health Study. Parkinson's Disease. 2020: 4038375. PMID 32399169 DOI: 10.1155/2020/4038375 |
0.382 |
|
| 2020 |
Bakshi R, Macklin EA, Hung AY, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Ascherio A, Scherzer CR, Schwarzschild MA. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. Journal of Parkinson's Disease. 10: 505-510. PMID 32250320 DOI: 10.3233/Jpd-191882 |
0.67 |
|
| 2020 |
Molsberry S, Bjornevik K, Hughes KC, Zhang ZJ, Jeanfavre S, Clish C, Healy B, Schwarzschild M, Ascherio A. Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease. Journal of Parkinson's Disease. PMID 32250318 DOI: 10.3233/Jpd-191896 |
0.347 |
|
| 2020 |
Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. PMID 32102975 DOI: 10.1212/Wnl.0000000000009107 |
0.472 |
|
| 2020 |
Bjornevik K, Schwarzschild MA, Ascherio A. Big health data and Parkinson's disease epidemiology: Challenges and opportunities. Parkinsonism & Related Disorders. 71: 58-59. PMID 31948788 DOI: 10.1016/J.Parkreldis.2020.01.001 |
0.367 |
|
| 2019 |
Hughes KC, Gao X, Molsberry S, Valeri L, Schwarzschild MA, Ascherio A. Physical activity and prodromal features of Parkinson disease. Neurology. PMID 31719136 DOI: 10.1212/Wnl.0000000000008567 |
0.35 |
|
| 2019 |
Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, Simuni T, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 31680121 DOI: 10.1038/S41436-019-0684-X |
0.38 |
|
| 2019 |
Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, Hung AY, Bwala G, Goetz CG, Russell DS, Goudreau JL, Parashos SA, Saint-Hilaire MH, Rudolph A, Hare JM, et al. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. PMID 31484712 DOI: 10.1212/Wnl.0000000000008194 |
0.439 |
|
| 2019 |
Bakshi R, Macklin EA, Logan R, Zorlu MM, Xia N, Crotty GF, Zhang E, Chen X, Ascherio A, Schwarzschild MA. Higher urate in LRRK2 mutation carriers resistant to Parkinson's disease. Annals of Neurology. PMID 30761591 DOI: 10.1002/Ana.25436 |
0.446 |
|
| 2019 |
Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, ... ... Schwarzschild MA, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 92: 329-337. PMID 30745444 DOI: 10.1212/Wnl.0000000000006926 |
0.383 |
|
| 2019 |
Ascherio A, Schwarzschild MA. Lifestyle and Parkinson's disease progression. Movement Disorders : Official Journal of the Movement Disorder Society. 34: 7-8. PMID 30653733 DOI: 10.1002/Mds.27566 |
0.427 |
|
| 2018 |
Chen X, Umeh CC, Tainsh RE, Feng DD, Maguire M, Zuo F, Rahimian M, Logan R, Wang X, Ascherio A, Macklin EA, Buys ES, Schwarzschild MA. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease. Ebiomedicine. PMID 30415890 DOI: 10.1016/J.Ebiom.2018.10.039 |
0.432 |
|
| 2018 |
Palacios N, Hughes KC, Cereda E, Schwarzschild MA, Ascherio A. Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30218460 DOI: 10.1002/Mds.109 |
0.43 |
|
| 2018 |
Iwaki H, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. The association between restless legs syndrome and premotor symptoms of Parkinson's disease. Journal of the Neurological Sciences. 394: 41-44. PMID 30212740 DOI: 10.1016/J.Jns.2018.08.028 |
0.424 |
|
| 2018 |
Hughes KC, Gao X, Baker JM, Stephen C, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-motor features of Parkinson's disease in a nested case-control study of US men. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 30076266 DOI: 10.1136/Jnnp-2018-318275 |
0.425 |
|
| 2018 |
Hughes KC, Gao X, O'Reilly EJ, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Genetic variants related to urate and risk of Parkinson's disease. Parkinsonism & Related Disorders. PMID 29789205 DOI: 10.1016/J.Parkreldis.2018.04.031 |
0.484 |
|
| 2018 |
Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Hannan MT, Betensky RA, Ascherio A. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts. Neurology. PMID 29643081 DOI: 10.1212/Wnl.0000000000005473 |
0.47 |
|
| 2018 |
Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. Ebiomedicine. PMID 29433982 DOI: 10.1016/J.Ebiom.2018.01.035 |
0.676 |
|
| 2018 |
Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, McCullough ML, Hannan MT, Betensky RA, Ascherio A. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29318639 DOI: 10.1002/Mds.27279 |
0.384 |
|
| 2017 |
Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use. Journal of Parkinson's Disease. PMID 28984617 DOI: 10.3233/Jpd-171175 |
0.452 |
|
| 2017 |
Ascherio A, Schwarzschild MA. Dietary antioxidants and Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 32: 1501-1503. PMID 28976040 DOI: 10.1002/Mds.27194 |
0.411 |
|
| 2017 |
Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Experimental Neurology. 298: 210-224. PMID 28622913 DOI: 10.1016/J.Expneurol.2017.06.017 |
0.456 |
|
| 2017 |
Hughes KC, Gao X, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of dairy foods and risk of Parkinson disease. Neurology. PMID 28596209 DOI: 10.1212/Wnl.0000000000004057 |
0.44 |
|
| 2017 |
Chen X, Feng D, Schwarzschild MA, Gao X. Red hair, MC1R variants, and risk for Parkinson's disease - a meta-analysis. Annals of Clinical and Translational Neurology. 4: 212-216. PMID 28275654 DOI: 10.1002/Acn3.381 |
0.423 |
|
| 2017 |
Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, et al. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28233927 DOI: 10.1002/Mds.26913 |
0.473 |
|
| 2016 |
Chen X, Chen H, Cai W, Maguire M, Ya B, Zuo F, Logan R, Li H, Robinson K, Vanderburg CR, Yu Y, Wang Y, Fisher DE, Schwarzschild MA. The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival. Annals of Neurology. PMID 28019657 DOI: 10.1002/Ana.24852 |
0.42 |
|
| 2016 |
Paganoni S, Schwarzschild MA. Urate as a Marker of Risk and Progression of Neurodegenerative Disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 27995438 DOI: 10.1007/S13311-016-0497-4 |
0.491 |
|
| 2016 |
Hughes KC, Gao X, Kim IY, Rimm EB, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of antioxidant vitamins and risk of parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 27787934 DOI: 10.1002/Mds.26819 |
0.406 |
|
| 2016 |
Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. The Lancet. Neurology. 15: 1257-1272. PMID 27751556 DOI: 10.1016/S1474-4422(16)30230-7 |
0.427 |
|
| 2016 |
Xu K, Luca DG, Orrú M, Xu Y, Chen JF, Schwarzschild MA. Neuroprotection by caffeine in the MPTP model of Parkinson's disease and its dependence on adenosine A2A receptors. Neuroscience. PMID 26905951 DOI: 10.1016/J.Neuroscience.2016.02.035 |
0.442 |
|
| 2016 |
Bhattacharyya S, Bakshi R, Logan R, Ascherio A, Macklin EA, Schwarzschild MA. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26805433 DOI: 10.1002/Mds.26483 |
0.417 |
|
| 2016 |
Gao X, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology. PMID 26764029 DOI: 10.1212/Wnl.0000000000002351 |
0.461 |
|
| 2016 |
Schwarzschild M, Fitzgerald K, Bakshi R, Macklin E, Scherzer C, Ascherio A. Association of α-synuclein gene expression with Parkinson’s disease is attenuated with higher serum urate in the PPMI cohort Parkinsonism & Related Disorders. 22: e115. DOI: 10.1016/J.Parkreldis.2015.10.265 |
0.316 |
|
| 2015 |
Bakshi R, Zhang H, Logan R, Joshi I, Xu Y, Chen X, Schwarzschild MA. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiology of Disease. PMID 26341543 DOI: 10.1016/J.Nbd.2015.08.022 |
0.39 |
|
| 2015 |
Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, et al. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain : a Journal of Neurology. 138: 2659-71. PMID 26220939 DOI: 10.1093/Brain/Awv202 |
0.65 |
|
| 2015 |
Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, Rauf NA, Wang H, Silverman RB, Ayata C, Maxwell MM, Steegborn C, Schwarzschild MA, Outeiro TF, Kazantsev AG. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. Plos One. 10: e0116919. PMID 25608039 DOI: 10.1371/Journal.Pone.0116919 |
0.416 |
|
| 2015 |
Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, et al. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease Brain. 138: 2659-2671. DOI: 10.1093/brain/awv202 |
0.589 |
|
| 2014 |
Palacios N, Fitzgerald KC, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. Particulate matter and risk of Parkinson disease in a large prospective study of women. Environmental Health : a Global Access Science Source. 13: 80. PMID 25294559 DOI: 10.1186/1476-069X-13-80 |
0.389 |
|
| 2014 |
Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A. Mendelian randomization of serum urate and parkinson disease progression. Annals of Neurology. 76: 862-8. PMID 25257975 DOI: 10.1002/Ana.24281 |
0.454 |
|
| 2014 |
Palacios N, Fitzgerald K, Roberts AL, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohort. Environmental Health Perspectives. 122: 933-8. PMID 24905870 DOI: 10.1289/Ehp.1307218 |
0.406 |
|
| 2014 |
Cipriani S, Bakshi R, Schwarzschild MA. Protection by inosine in a cellular model of Parkinson's disease. Neuroscience. 274: 242-9. PMID 24880154 DOI: 10.1016/J.Neuroscience.2014.05.038 |
0.386 |
|
| 2014 |
Kachroo A, Schwarzschild MA. Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease. Brain Research. 1563: 103-9. PMID 24680743 DOI: 10.1016/J.Brainres.2014.03.031 |
0.417 |
|
| 2014 |
Wong JC, Li Y, Schwarzschild MA, Ascherio A, Gao X. Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep. 37: 369-72. PMID 24497665 DOI: 10.5665/Sleep.3416 |
0.418 |
|
| 2014 |
McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss. Plos One. 9: e86048. PMID 24465863 DOI: 10.1371/Journal.Pone.0086048 |
0.717 |
|
| 2014 |
Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. Jama Neurology. 71: 141-50. PMID 24366103 DOI: 10.1001/Jamaneurol.2013.5528 |
0.421 |
|
| 2014 |
Hung AY, Schwarzschild MA. Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 34-46. PMID 24310604 DOI: 10.1007/S13311-013-0239-9 |
0.432 |
|
| 2013 |
Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, ... ... Schwarzschild MA, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 81: 1531-7. PMID 24068787 DOI: 10.1212/Wnl.0B013E3182A95818 |
0.629 |
|
| 2013 |
Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. Journal of Parkinson's Disease. 3: 231-9. PMID 24018336 DOI: 10.3233/Jpd-139000 |
0.426 |
|
| 2013 |
McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA. Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders. Neuro-Degenerative Diseases. 12: 189-98. PMID 23467193 DOI: 10.1159/000346370 |
0.682 |
|
| 2013 |
Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 380-3. PMID 23339054 DOI: 10.1002/Mds.25319 |
0.44 |
|
| 2013 |
Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, Xu Y, Schwarzschild MA. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. 110: 300-5. PMID 23248282 DOI: 10.1073/Pnas.1217296110 |
0.456 |
|
| 2013 |
Burdett TC, Desjardins CA, Logan R, McFarland NR, Chen X, Schwarzschild MA. Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomedical Chromatography : Bmc. 27: 122-9. PMID 22674671 DOI: 10.1002/Bmc.2760 |
0.575 |
|
| 2013 |
McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA, Nocker M, Scherfler C, Kiechl S, Willeit J, Schmidauer C, Gasperi A, Rungger G, Poewe W, Mahlknecht P, Seppi K, et al. Contents Vol. 12, 2013 Neurodegenerative Diseases. 12. DOI: 10.1159/000355887 |
0.546 |
|
| 2012 |
Palacios N, Gao X, Schwarzschild M, Ascherio A. Declining quality of life in Parkinson disease before and after diagnosis. Journal of Parkinson's Disease. 2: 153-60. PMID 23939439 DOI: 10.3233/Jpd-2012-12083 |
0.378 |
|
| 2012 |
Gao X, Simon KC, Schwarzschild MA, Ascherio A. Age, statin use, and the risk for incident Parkinson disease-reply. Archives of Neurology. 69: 1381. PMID 23754004 DOI: 10.1001/Archneurol.2012.2032 |
0.369 |
|
| 2012 |
Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1392-7. PMID 22976926 DOI: 10.1002/Mds.25157 |
0.39 |
|
| 2012 |
Palacios N, Gao X, McCullough ML, Schwarzschild MA, Shah R, Gapstur S, Ascherio A. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1276-82. PMID 22927157 DOI: 10.1002/Mds.25076 |
0.412 |
|
| 2012 |
Schwarzschild MA. Caffeine in Parkinson disease: better for cruise control than snooze patrol? Neurology. 79: 616-8. PMID 22855870 DOI: 10.1212/Wnl.0B013E318263580E |
0.392 |
|
| 2012 |
Palacios N, Gao X, O'Reilly E, Schwarzschild M, McCullough ML, Mayo T, Gapstur SM, Ascherio AA. Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 980-7. PMID 22714720 DOI: 10.1002/Mds.25050 |
0.337 |
|
| 2012 |
Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. Journal of Neurochemistry. 123: 172-81. PMID 22671773 DOI: 10.1111/J.1471-4159.2012.07820.X |
0.337 |
|
| 2012 |
Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. Plos One. 7: e37331. PMID 22606360 DOI: 10.1371/Journal.Pone.0037331 |
0.333 |
|
| 2012 |
Chen X, Wu G, Schwarzschild MA. Urate in Parkinson's disease: more than a biomarker? Current Neurology and Neuroscience Reports. 12: 367-75. PMID 22580741 DOI: 10.1007/S11910-012-0282-7 |
0.494 |
|
| 2012 |
Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology. 78: 1138-45. PMID 22491871 DOI: 10.1212/Wnl.0B013E31824F7Fc4 |
0.409 |
|
| 2012 |
Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Archives of Neurology. 69: 380-4. PMID 22410446 DOI: 10.1001/Archneurol.2011.1060 |
0.438 |
|
| 2012 |
Kachroo A, Schwarzschild MA. Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease. Annals of Neurology. 71: 278-82. PMID 22367999 DOI: 10.1002/Ana.22630 |
0.445 |
|
| 2012 |
Palacios N, Gao X, Schwarzschild M, Ascherio A. Declining Quality of Life in Parkinson Disease Patients before and after Diagnosis (P06.064) Neurology. 78: P06.064-P06.064. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P06.064 |
0.315 |
|
| 2012 |
Palacios N, Roberts A, Weisskopf M, Schwarzschild M, Laden F, Ascherio A. E-002: Exposure to Airborne Metals and risk of Parkinson Disease in a Prospective Study of US Women Epidemiology. 23: 1. DOI: 10.1097/01.Ede.0000416602.63176.B5 |
0.328 |
|
| 2012 |
Chen X, Burdett T, Desjardins C, Xu Y, Schwarzschild MA. 3.245 Effects Of Urate Oxidase Transgene Or Knockout In A Mouse Model Of Parkinson'S Disease Parkinsonism & Related Disorders. 18. DOI: 10.1016/S1353-8020(11)70917-8 |
0.408 |
|
| 2012 |
Gao X, Simon K, Schwarzschild M, Ascherio A. 1.120 A PROSPECTIVE STUDY OF STATIN USE AND RISK OF PARKINSON DISEASE Parkinsonism & Related Disorders. 18: S40. DOI: 10.1016/S1353-8020(11)70234-6 |
0.401 |
|
| 2011 |
Ding H, Sarokhan AK, Roderick SS, Bakshi R, Maher NE, Ashourian P, Kan CG, Chang S, Santarlasci A, Swords KE, Ravina BM, Hayes MT, Sohur US, Wills AM, Flaherty AW, ... ... Schwarzschild MA, et al. Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2283-6. PMID 21953863 DOI: 10.1002/Mds.23934 |
0.645 |
|
| 2011 |
Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H. Serum cholesterol and the progression of parkinson's disease: Results from DATATOP Plos One. 6. PMID 21853051 DOI: 10.1371/Journal.Pone.0022854 |
0.45 |
|
| 2011 |
Palacios N, Gao X, McCullough ML, Jacobs EJ, Patel AV, Mayo T, Schwarzschild MA, Ascherio A. Obesity, diabetes, and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2253-9. PMID 21739472 DOI: 10.1002/Mds.23855 |
0.372 |
|
| 2011 |
Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson's disease. American Journal of Epidemiology. 174: 546-51. PMID 21719744 DOI: 10.1093/Aje/Kwr119 |
0.337 |
|
| 2011 |
Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1864-8. PMID 21538532 DOI: 10.1002/Mds.23741 |
0.396 |
|
| 2011 |
Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 76: 863-9. PMID 21368281 DOI: 10.1212/Wnl.0B013E31820F2D79 |
0.45 |
|
| 2011 |
Barkhoudarian MT, Schwarzschild MA. Preclinical jockeying on the translational track of adenosine A2A receptors. Experimental Neurology. 228: 160-4. PMID 21211537 DOI: 10.1016/J.Expneurol.2010.12.022 |
0.392 |
|
| 2011 |
Xiao D, Cassin JJ, Healy B, Burdett TC, Chen JF, Fredholm BB, Schwarzschild MA. Deletion of adenosine Aâ‚ or A(â‚‚A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Research. 1367: 310-8. PMID 20828543 DOI: 10.1016/J.Brainres.2010.08.099 |
0.409 |
|
| 2010 |
Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomarkers in Medicine. 4: 701-12. PMID 20945982 DOI: 10.2217/Bmm.10.94 |
0.478 |
|
| 2010 |
Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Neuroscience Letters. 486: 161-5. PMID 20854878 DOI: 10.1016/J.Neulet.2010.09.043 |
0.426 |
|
| 2010 |
Gardener H, Gao X, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Prenatal and early life factors and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1560-7. PMID 20740569 DOI: 10.1002/Mds.23339 |
0.422 |
|
| 2010 |
Gao X, Schwarzschild MA, O'Reilly EJ, Wang H, Ascherio A. Restless legs syndrome and Parkinson's disease in men. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2654-7. PMID 20737545 DOI: 10.1002/Mds.23256 |
0.445 |
|
| 2010 |
Morelli M, Carta AR, Kachroo A, Schwarzschild MA. Pathophysiological roles for purines: adenosine, caffeine and urate. Progress in Brain Research. 183: 183-208. PMID 20696321 DOI: 10.1016/S0079-6123(10)83010-9 |
0.473 |
|
| 2010 |
O'Reilly EJ, Gao X, Weisskopf MG, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Plasma urate and Parkinson's disease in women. American Journal of Epidemiology. 172: 666-70. PMID 20682521 DOI: 10.1093/Aje/Kwq195 |
0.339 |
|
| 2010 |
Simon KC, Gao X, Chen H, Schwarzschild MA, Ascherio A. Calcium channel blocker use and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1818-22. PMID 20669249 DOI: 10.1002/Mds.23191 |
0.452 |
|
| 2010 |
Palacios N, Weisskopf M, Simon K, Gao X, Schwarzschild M, Ascherio A. Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. Parkinsonism & Related Disorders. 16: 370-5. PMID 20304699 DOI: 10.1016/J.Parkreldis.2010.02.012 |
0.403 |
|
| 2010 |
Kachroo A, Irizarry MC, Schwarzschild MA. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Experimental Neurology. 223: 657-61. PMID 20188092 DOI: 10.1016/J.Expneurol.2010.02.007 |
0.446 |
|
| 2010 |
Schwarzschild MA. Rasagiline in Parkinson's disease. The New England Journal of Medicine. 362: 658; author reply 65. PMID 20187261 |
0.317 |
|
| 2010 |
Xu K, Xu YH, Chen JF, Schwarzschild MA. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience. 167: 475-81. PMID 20167258 DOI: 10.1016/J.Neuroscience.2010.02.020 |
0.41 |
|
| 2009 |
Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 73: 1286-91. PMID 19841380 DOI: 10.1212/Wnl.0B013E3181Bd13A1 |
0.449 |
|
| 2009 |
Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, ... ... Schwarzschild MA, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Archives of Neurology. 66: 1460-8. PMID 19822770 DOI: 10.1001/Archneurol.2009.247 |
0.409 |
|
| 2009 |
Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. Journal of Neurochemistry. 111: 1478-89. PMID 19817968 DOI: 10.1111/J.1471-4159.2009.06425.X |
0.445 |
|
| 2009 |
McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. Journal of Neuropathology and Experimental Neurology. 68: 515-24. PMID 19525899 DOI: 10.1097/Nen.0B013E3181A24B53 |
0.738 |
|
| 2009 |
Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 1359-65. PMID 19424986 DOI: 10.1002/Mds.22619 |
0.441 |
|
| 2009 |
Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. Annals of Neurology. 65: 76-82. PMID 19194882 DOI: 10.1002/Ana.21535 |
0.463 |
|
| 2009 |
Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, English P, Goldman S, Grate S, Hansen J, Hoppin J, Jewell S, Kamel F, Koroshetz W, Langston JW, ... ... Schwarzschild M, et al. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environmental Health Perspectives. 117: 117-21. PMID 19165397 DOI: 10.1289/Ehp.11702 |
0.463 |
|
| 2009 |
O'Reilly EJ, Chen H, Gardener H, Gao X, Schwarzschild MA, Ascherio A. Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality. American Journal of Epidemiology. 169: 678-82. PMID 19131566 DOI: 10.1093/Aje/Kwn388 |
0.35 |
|
| 2009 |
Petzer JP, Castagnoli N, Schwarzschild MA, Chen JF, Van der Schyf CJ. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 141-51. PMID 19110205 DOI: 10.1016/J.Nurt.2008.10.035 |
0.419 |
|
| 2008 |
Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Archives of Neurology. 65: 716-23. PMID 18413464 DOI: 10.1001/Archneur.2008.65.6.Nct70003 |
0.438 |
|
| 2008 |
Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. American Journal of Epidemiology. 167: 831-8. PMID 18326873 DOI: 10.1093/Aje/Kwm385 |
0.454 |
|
| 2008 |
Gao X, Chen H, Schwarzschild MA, Logroscino G, Ascherio A. Perceived imbalance and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 613-6. PMID 18181208 DOI: 10.1002/Mds.21919 |
0.472 |
|
| 2008 |
Wang H, Chen H, Gao X, McGrath M, Deer D, De Vivo I, Schwarzschild MA, Ascherio A. Telomere length and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 302-5. PMID 18044760 DOI: 10.1002/Mds.21867 |
0.459 |
|
| 2008 |
Thacker EL, Chen H, Patel AV, McCullough ML, Calle EE, Thun MJ, Schwarzschild MA, Ascherio A. Recreational physical activity and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 69-74. PMID 17960818 DOI: 10.1002/Mds.21772 |
0.42 |
|
| 2008 |
Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. American Journal of Epidemiology. 167: 90-5. PMID 17890755 DOI: 10.1093/Aje/Kwm260 |
0.357 |
|
| 2008 |
McFarland NR, Schwarzschild MA. Is Mortality Increased with Essential Tremor Nejm Journal Watch. 2008. DOI: 10.1056/Jn200803110000003 |
0.57 |
|
| 2007 |
Schwarzschild MA. Adenosine A2A antagonists as neurotherapeutics: crossing the bridge. Progress in Neurobiology. 83: 261-2. PMID 17997007 DOI: 10.1016/J.Pneurobio.2007.10.002 |
0.342 |
|
| 2007 |
Gao X, Chen H, Fung TT, Logroscino G, Schwarzschild MA, Hu FB, Ascherio A. Prospective study of dietary pattern and risk of Parkinson disease. The American Journal of Clinical Nutrition. 86: 1486-94. PMID 17991663 DOI: 10.1093/Ajcn/86.5.1486 |
0.417 |
|
| 2007 |
Gao X, Chen H, Schwarzschild MA, Glasser DB, Logroscino G, Rimm EB, Ascherio A. Erectile function and risk of Parkinson's disease. American Journal of Epidemiology. 166: 1446-50. PMID 17875583 DOI: 10.1093/Aje/Kwm246 |
0.379 |
|
| 2007 |
Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Progress in Neurobiology. 83: 293-309. PMID 17826884 DOI: 10.1016/J.Pneurobio.2007.07.001 |
0.417 |
|
| 2007 |
Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 69: 1688-95. PMID 17761552 DOI: 10.1212/01.Wnl.0000271883.45010.8A |
0.431 |
|
| 2007 |
Hung AY, Schwarzschild MA. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Current Opinion in Neurology. 20: 477-83. PMID 17620885 DOI: 10.1097/Wco.0B013E32826388D6 |
0.385 |
|
| 2007 |
Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. American Journal of Epidemiology. 166: 561-7. PMID 17584757 DOI: 10.1093/Aje/Kwm127 |
0.453 |
|
| 2007 |
Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 68: 764-8. PMID 17339584 DOI: 10.1212/01.Wnl.0000256374.50227.4B |
0.33 |
|
| 2007 |
Chen H, O'Reilly E, McCullough ML, Rodriguez C, Schwarzschild MA, Calle EE, Thun MJ, Ascherio A. Consumption of dairy products and risk of Parkinson's disease. American Journal of Epidemiology. 165: 998-1006. PMID 17272289 DOI: 10.1093/Aje/Kwk089 |
0.32 |
|
| 2007 |
Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. Molecular markers of early Parkinson's disease based on gene expression in blood. Proceedings of the National Academy of Sciences of the United States of America. 104: 955-60. PMID 17215369 DOI: 10.1073/Pnas.0610204104 |
0.623 |
|
| 2006 |
Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS, Chen JF, Schwarzschild MA. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 13548-55. PMID 17192438 DOI: 10.1523/Jneurosci.3554-06.2006 |
0.407 |
|
| 2006 |
Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends in Neurosciences. 29: 647-54. PMID 17030429 DOI: 10.1016/J.Tins.2006.09.004 |
0.466 |
|
| 2006 |
Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews. Drug Discovery. 5: 845-54. PMID 17016425 DOI: 10.1038/Nrd2087 |
0.41 |
|
| 2006 |
Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, Schwarzschild MA, Thun MJ. Pesticide exposure and risk for Parkinson's disease. Annals of Neurology. 60: 197-203. PMID 16802290 DOI: 10.1002/Ana.20904 |
0.447 |
|
| 2006 |
Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1002-7. PMID 16602107 DOI: 10.1002/Mds.20881 |
0.458 |
|
| 2006 |
Chen H, Schernhammer E, Schwarzschild MA, Ascherio A. A prospective study of night shift work, sleep duration, and risk of Parkinson's disease. American Journal of Epidemiology. 163: 726-30. PMID 16495472 DOI: 10.1093/Aje/Kwj096 |
0.319 |
|
| 2006 |
Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 535-41. PMID 16407551 DOI: 10.1523/Jneurosci.3008-05.2006 |
0.438 |
|
| 2006 |
Yu L, Schwarzschild MA, Chen JF. Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice. Neuroscience Letters. 393: 31-5. PMID 16236444 DOI: 10.1016/J.Neulet.2005.09.036 |
0.33 |
|
| 2006 |
Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, Thun MJ, Schwarzschild MA, Ascherio A. Prospective Study Of Education, Occupation, and Risk of Parkinson's Disease American Journal of Epidemiology. 163. DOI: 10.1093/Aje/163.Suppl_11.S178-C |
0.375 |
|
| 2005 |
Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Annals of Neurology. 58: 963-7. PMID 16240369 DOI: 10.1002/Ana.20682 |
0.451 |
|
| 2005 |
Hauser RA, Schwarzschild MA. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs & Aging. 22: 471-482. PMID 15974638 DOI: 10.2165/00002512-200522060-00002 |
0.481 |
|
| 2005 |
Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacology & Therapeutics. 105: 267-310. PMID 15737407 DOI: 10.1016/J.Pharmthera.2004.10.007 |
0.423 |
|
| 2005 |
Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Physical activity and the risk of Parkinson disease Neurology. 64: 664-669. PMID 15728289 DOI: 10.1212/01.Wnl.0000151960.28687.93 |
0.442 |
|
| 2004 |
Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Logroscino G, Willett WC, Ascherio A. Folate Intake and Risk of Parkinson’s Disease American Journal of Epidemiology. 160: 368-375. PMID 15286022 DOI: 10.1093/Aje/Kwh213 |
0.4 |
|
| 2004 |
Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Willett WC, Ascherio A. Obesity and the Risk of Parkinson’s Disease American Journal of Epidemiology. 159: 547-555. PMID 15003958 DOI: 10.1093/Aje/Kwh059 |
0.422 |
|
| 2004 |
Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Molecular Pharmacology. 65: 121-9. PMID 14722243 DOI: 10.1124/Mol.65.1.121 |
0.32 |
|
| 2003 |
Chen JF, Fredduzzi S, Bastia E, Yu L, Moratalla R, Ongini E, Schwarzschild MA. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease. Neurology. 61: S74-81. PMID 14663016 DOI: 10.1212/01.Wnl.0000095218.26363.7B |
0.423 |
|
| 2003 |
Castagnoli N, Petzer JP, Steyn S, Castagnoli K, Chen JF, Schwarzschild MA, Van der Schyf CJ. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists. Neurology. 61: S62-8. PMID 14663013 DOI: 10.1212/01.Wnl.0000095215.97585.59 |
0.437 |
|
| 2003 |
Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N, Chen JF. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology. 61: S55-61. PMID 14663012 DOI: 10.1212/01.Wnl.0000095214.53646.72 |
0.471 |
|
| 2003 |
Chen J, Chase T, Schwarzschild M. J. Stephen Fink, MD, PhD (1950–2002) Neurology. 61. PMID 14663000 DOI: 10.1212/01.Wnl.0000095201.55121.8A |
0.381 |
|
| 2003 |
Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Chen JF, Schwarzschild MA, Chase TN. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Experimental Neurology. 184: 285-94. PMID 14637099 DOI: 10.1016/S0014-4886(03)00250-4 |
0.387 |
|
| 2003 |
Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A. Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease Jama Neurology. 60: 1059-1064. PMID 12925360 DOI: 10.1001/Archneur.60.8.1059 |
0.459 |
|
| 2003 |
Hernán MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson's disease Annals of Neurology. 54: 170-175. PMID 12891669 DOI: 10.1002/Ana.10611 |
0.431 |
|
| 2003 |
Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease Movement Disorders. 18: 646-651. PMID 12784267 DOI: 10.1002/Mds.10425 |
0.451 |
|
| 2003 |
Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease Neurology. 60: 790-795. PMID 12629235 DOI: 10.1212/01.Wnl.0000046523.05125.87 |
0.399 |
|
| 2003 |
Petzer JP, Steyn S, Castagnoli KP, Chen JF, Schwarzschild MA, Van der Schyf CJ, Castagnoli N. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry. 11: 1299-310. PMID 12628657 DOI: 10.1016/S0968-0896(02)00648-X |
0.375 |
|
| 2003 |
Gomez-Isla T, Irizarry MC, Mariash A, Cheung B, Soto O, Schrump S, Sondel J, Kotilinek L, Day J, Schwarzschild MA, Cha JH, Newell K, Miller DW, Uéda K, Young AB, et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiology of Aging. 24: 245-58. PMID 12498958 DOI: 10.1016/S0197-4580(02)00091-X |
0.497 |
|
| 2003 |
Schwarzschild MA, Chen JF, Chase TN. A2A antagonists for PD: A prime example of translational neuroscience Neurology. 61: S3-S4. DOI: 10.1212/01.Wnl.0000095202.94814.0F |
0.438 |
|
| 2003 |
Chen J, Schwarzschild MA. Gene knockout approach to adenosine A2A receptors in Parkinson's disease Drug Development Research. 58: 354-367. DOI: 10.1002/Ddr.10215 |
0.39 |
|
| 2002 |
Chen JF, Steyn S, Staal R, Petzer JP, Xu K, Van Der Schyf CJ, Castagnoli K, Sonsalla PK, Castagnoli N, Schwarzschild MA. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. The Journal of Biological Chemistry. 277: 36040-4. PMID 12130655 DOI: 10.1074/Jbc.M206830200 |
0.317 |
|
| 2002 |
Schwarzschild MA, Chen J, Ascherio A. Caffeinated clues and the promise of adenosine A2A antagonists in PD Neurology. 58: 1154-1160. PMID 11971080 DOI: 10.1212/Wnl.58.8.1154 |
0.461 |
|
| 2002 |
Xu K, Xu YH, Chen JF, Schwarzschild MA. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neuroscience Letters. 322: 13-6. PMID 11958832 DOI: 10.1016/S0304-3940(02)00069-1 |
0.308 |
|
| 2001 |
Gearan T, Castillo OA, Schwarzschild MA. The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures. Parkinsonism & Related Disorders. 8: 19-22. PMID 11472876 DOI: 10.1016/S1353-8020(00)00078-X |
0.333 |
|
| 2001 |
Chen J, Xu K, Petzer JP, Staal R, Xu Y, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N, Schwarzschild MA. Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease The Journal of Neuroscience. 21: RC143-RC143. DOI: 10.1523/Jneurosci.21-10-J0001.2001 |
0.486 |
|
| 2001 |
Ongini E, Monopoli A, Impagnatiello F, Fredduzzi S, Schwarzschild M, Chen J. Dual actions of A2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes Drug Development Research. 52: 379-386. DOI: 10.1002/Ddr.1137 |
0.339 |
|
| Show low-probability matches. |